Comprehensive NTRK Fusion Detection, Agnostic of the Fusion Partner, for Optimal Identification of Rare Genomic Events Using TruSightTM Oncology 500

Presented at: Drug Discovery Virtual Event Series 2019

Sponsored by: Illumina

Speakers

Phillip Febbo, MD

Chief Medical Officer, Illumina, Inc.
BIOGRAPHY
Maude Champagne

Clinical Oncology Marketing, Illumina, Inc.
BIOGRAPHY

Abstract

NTRK fusions are rare but important recent biomarkers linked to response to new TRK inhibitors. Comprehensive genomic profiling on all solid tumors permits detection of rare genomic events and in the future may enables the use of emerging treatments such as NTRK inhibitors. NTRK genes include numerous potential fusion partners, large intronic regions and G-C rich content, making accurate and comprehensive detection of NTRK fusions difficult to perform in the lab. Amongst the variable performance of NTRK fusion assays, NTRK detection from RNA using Hybrid-Capture NGS provides comprehensive and accurate fusion detection, agnostic of the fusion partner. TruSightTM Oncology 500 is the latest comprehensive genomic profiling assay from Illumina and enables optimal NTRK fusion detection.

Learning Objectives:

1. Value to adopt comprehensive genomic profiling in today's oncology care.
2. How the Illumina TruSightTM Oncology 500 comprehensive genomic profiling assay enables optimal NTRK fusion detection.